Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TSHA | PRESS-RELEASE | neutral | 1/10 | Taysha Gene Therapies, Inc. announced it will report its Q1 2026 results on May 6. | Apr 29, 2026 |
| RNTX | PRESS-RELEASE | neutral | 3/10 | Rein Therapeutics provided a clinical update on its Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis (IPF | Apr 29, 2026 |
| TPST | PRESS-RELEASE | bullish | 5/10 | Tempest Therapeutics will present updated clinical data for TPST-2003 at the ISCT meeting, building on earlier positive | Apr 29, 2026 |
| EBS | PRESS-RELEASE | bullish | 4/10 | Emergent BioSolutions announced a multi-year agreement with SAB Biotherapeutics to provide manufacturing services for SA | Apr 29, 2026 |
| TEVA | PRESS-RELEASE | mixed | 6/10 | Teva reported Q1 2026 non-GAAP EPS of $0.53, beating consensus of $0.46 by 15%, and revenue of $3.98B, beating $3.79B by | Apr 29, 2026 |
| OCGN | PRESS-RELEASE | neutral | 1/10 | Ocugen announced it will host a conference call on May 5 to discuss its Q1 2026 results. | Apr 29, 2026 |
| EBS | PRESS-RELEASE | neutral | 1/10 | Emergent BioSolutions announced a partnership with baseball player Davis Schneider to promote awareness of NARCAN Nasal | Apr 29, 2026 |
| TEVA | PRESS-RELEASE | bullish | 6/10 | Teva acquires Emalex Biosciences for $700M upfront plus up to $200M in milestones and royalties, gaining ecopipam, a lat | Apr 29, 2026 |
| AGIO | PRESS-RELEASE | bullish | 6/10 | Agios Pharmaceuticals reported Q1 2026 revenue of $20.7M (beat $13.6M consensus by 53%) and EPS of -$1.69 (beat -$1.79 c | Apr 29, 2026 |
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast announced that its Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain due to degenerative | Apr 28, 2026 |
| ORKA | PRESS-RELEASE | bearish | 6/10 | Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, raising ap | Apr 28, 2026 |
| DSGN | PRESS-RELEASE | bullish | 5/10 | Design Therapeutics reported Q1 2026 net loss per share of $(0.29), beating consensus of $(0.33) by 12%. The company hig | Apr 28, 2026 |
| ARTL | PRESS-RELEASE | neutral | 3/10 | Artelo Biosciences announced a strategic partnership with AI company ScienceMachine to accelerate development of its FAB | Apr 28, 2026 |
| EBS | PRESS-RELEASE | neutral | 4/10 | Emergent BioSolutions announced a ~$34.5M agreement with Substipharm Biologics to manufacture drug substance for the IMO | Apr 28, 2026 |
| LEGN | PRESS-RELEASE | neutral | 1/10 | Legend Biotech USA Inc. announced it will host a conference call on May 12, 2026 to discuss its Q1 2026 results. | Apr 28, 2026 |
| PRFX | PRESS-RELEASE | neutral | 4/10 | PRF Technologies announced FDA clearance of its IND application for OcuRing™-K, a sustained-release intraocular ring for | Apr 28, 2026 |
| CYTK | PRESS-RELEASE | neutral | 3/10 | Cytokinetics announced nine presentations at the ESC Heart Failure 2026 Congress, including a late-breaking oral present | Apr 28, 2026 |
| WVE | PRESS-RELEASE | bullish | 7/10 | Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs consensus -$0.31), repr | Apr 28, 2026 |
| PSTV | PRESS-RELEASE | neutral | 3/10 | Plus Therapeutics subsidiary CNSide Diagnostics secured a new payer coverage agreement with Blue Shield of California, e | Apr 28, 2026 |
| KNSA | PRESS-RELEASE | bullish | 8/10 | Kiniksa reported Q1 2026 revenue of $214.3M (56% YoY growth) and GAAP diluted EPS of $0.27, beating consensus EPS of $0. | Apr 28, 2026 |
| ACRS | PRESS-RELEASE | bullish | 7/10 | Aclaris reported positive full Phase 1a results for ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing a 45-day h | Apr 28, 2026 |
| BMEA | PRESS-RELEASE | bullish | 6/10 | Biomea Fusion reported positive 52-week Phase 2 data for icovamenib in type 1 diabetes, showing a 52% increase in C-pept | Apr 27, 2026 |
| HRTX | PRESS-RELEASE | neutral | 1/10 | Heron Therapeutics, Inc. announced it will report its Q1 2026 results on May 11, 2026. | Apr 27, 2026 |
| TSHA | PRESS-RELEASE | bullish | 6/10 | Taysha Gene Therapies announced positive preclinical in vitro data for TSHA-102, showing scAAV9 enables ~30-fold higher | Apr 27, 2026 |
| VYGR | PRESS-RELEASE | neutral | 5/10 | Voyager Therapeutics announced eight presentations at ASGCT 2026, headlined by late-breaking oral data on VY1706, a tau- | Apr 27, 2026 |
| ORKA | PRESS-RELEASE | bearish | 6/10 | Oruka Therapeutics announced a $500M underwritten public offering of common stock and pre-funded warrants, with an addit | Apr 27, 2026 |
| GPCR | PRESS-RELEASE | neutral | 2/10 | Structure Therapeutics announced multiple presentations at the ADA 86th Scientific Sessions, including an oral presentat | Apr 27, 2026 |
| NTLA | PRESS-RELEASE | bearish | 6/10 | Intellia Therapeutics announced an underwritten public offering of $150 million in common stock, with an underwriter opt | Apr 27, 2026 |
| ERAS | PRESS-RELEASE | bullish | 8/10 | Erasca reported highly positive preliminary Phase 1 data for pan-RAS inhibitor ERAS-0015, showing 62% uORR in 2L+ KRAS G | Apr 27, 2026 |
| TOI | PRESS-RELEASE | neutral | 1/10 | TOI Management, LLC announced it will report its Q1 2026 results on May 7, 2026. | Apr 27, 2026 |